iPSC-based modeling of THD recapitulates disease phenotypes and reveals neuronal malformation

EMBO Mol Med. 2023 Mar 8;15(3):e15847. doi: 10.15252/emmm.202215847. Epub 2023 Feb 6.

Abstract

Tyrosine hydroxylase deficiency (THD) is a rare genetic disorder leading to dopaminergic depletion and early-onset Parkinsonism. Affected children present with either a severe form that does not respond to L-Dopa treatment (THD-B) or a milder L-Dopa responsive form (THD-A). We generated induced pluripotent stem cells (iPSCs) from THD patients that were differentiated into dopaminergic neurons (DAn) and compared with control-DAn from healthy individuals and gene-corrected isogenic controls. Consistent with patients, THD iPSC-DAn displayed lower levels of DA metabolites and reduced TH expression, when compared to controls. Moreover, THD iPSC-DAn showed abnormal morphology, including reduced total neurite length and neurite arborization defects, which were not evident in DAn differentiated from control-iPSC. Treatment of THD-iPSC-DAn with L-Dopa rescued the neuronal defects and disease phenotype only in THDA-DAn. Interestingly, L-Dopa treatment at the stage of neuronal precursors could prevent the alterations in THDB-iPSC-DAn, thus suggesting the existence of a critical developmental window in THD. Our iPSC-based model recapitulates THD disease phenotypes and response to treatment, representing a promising tool for investigating pathogenic mechanisms, drug screening, and personalized management.

Keywords: L-Dopa; Parkinsonism; dopamine; iPSC; tyrosine hydroxylase deficiency.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Dopaminergic Neurons / metabolism
  • Humans
  • Induced Pluripotent Stem Cells* / metabolism
  • Levodopa* / metabolism
  • Levodopa* / therapeutic use
  • Phenotype

Substances

  • Levodopa

Supplementary concepts

  • Segawa syndrome, autosomal recessive